{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T02:04:33Z","timestamp":1782439473451,"version":"3.54.5"},"reference-count":74,"publisher":"Edizioni Minerva Medica","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Panminerva Med"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.23736\/s0031-0808.25.05339-x","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T12:08:37Z","timestamp":1753790917000},"source":"Crossref","is-referenced-by-count":1,"title":["Glucagon-like peptide-1 receptor analogues and beyond: emerging obesity pharmacotherapies"],"prefix":"10.23736","volume":"67","author":[{"given":"Kaivalya","family":"ABBURI","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eka","family":"MELSON","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander D.","family":"MIRAS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitris","family":"PAPAMARGARITIS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"17149","reference":[{"key":"10.23736\/S0031-0808.25.05339-X_ref001","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19897"},{"key":"10.23736\/S0031-0808.25.05339-X_ref002","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.13022"},{"key":"10.23736\/S0031-0808.25.05339-X_ref003","doi-asserted-by":"publisher","DOI":"10.1172\/JCI140065"},{"key":"10.23736\/S0031-0808.25.05339-X_ref004","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.19-3-205"},{"key":"10.23736\/S0031-0808.25.05339-X_ref005","doi-asserted-by":"publisher","DOI":"10.7326\/AITC202205170"},{"key":"10.23736\/S0031-0808.25.05339-X_ref006","unstructured":"Obesity - Diagnosis and treatment - Mayo Clinic [Internet]. Available from: https:\/\/www.mayoclinic.org\/diseases-conditions\/obesity\/diagnosis-treatment\/drc-20375749?utm_source=chatgpt.com [cited 2025, Jan 24]."},{"key":"10.23736\/S0031-0808.25.05339-X_ref007","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-024-01113-9"},{"key":"10.23736\/S0031-0808.25.05339-X_ref008","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01931-z"},{"key":"10.23736\/S0031-0808.25.05339-X_ref009","doi-asserted-by":"publisher","DOI":"10.2337\/db23-79-LB"},{"key":"10.23736\/S0031-0808.25.05339-X_ref010","unstructured":"Metsera. Metsera News: Latest Updates [Internet]. Available from: https:\/\/metsera.com\/news\/ [cited 2025, Jan 31]."},{"key":"10.23736\/S0031-0808.25.05339-X_ref011","doi-asserted-by":"publisher","DOI":"10.2337\/db24-1858-LB"},{"key":"10.23736\/S0031-0808.25.05339-X_ref012","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038"},{"key":"10.23736\/S0031-0808.25.05339-X_ref013","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-024-01473-y"},{"key":"10.23736\/S0031-0808.25.05339-X_ref014","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2024.2356254"},{"key":"10.23736\/S0031-0808.25.05339-X_ref015","unstructured":"Novo Nordisk. News Details [Internet]. Available from: https:\/\/www.novonordisk.com\/content\/nncorp\/global\/en\/news-and-media\/news-and-ir-materials\/news-details.html [cited 2025, Jan 24]."},{"key":"10.23736\/S0031-0808.25.05339-X_ref016","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-022-09735-8"},{"key":"10.23736\/S0031-0808.25.05339-X_ref017","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0749"},{"key":"10.23736\/S0031-0808.25.05339-X_ref018","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01185-6"},{"key":"10.23736\/S0031-0808.25.05339-X_ref019","unstructured":"Garvey WT. Efficacy and safety of oral semaglutide 25 mg in adults with overweight\/obesity: the OASIS 4 RCT 42nd Annual Meeting of The Obesity Society (TOS) held at Obesity Week; 2024 Nov 3. San Antonio, TX, USA [Internet]. Available from: file:\/\/\/C:\/Users\/kaiva\/Downloads\/Garvey_OASIS_4_OW24-oral_Final_23Oct24%20(3).pdf [cited 2025, Feb 20]."},{"key":"10.23736\/S0031-0808.25.05339-X_ref020","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2302392"},{"key":"10.23736\/S0031-0808.25.05339-X_ref021","unstructured":"Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity | Pfizer [Internet]. Available from: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-announces-topline-phase-2b-results-oral-glp-1r [cited 2025, Jan 31]."},{"key":"10.23736\/S0031-0808.25.05339-X_ref022","unstructured":"Therapeutics R. Regor Releases Phase 2a Topline Results for RGT-075, an Oral Once-daily Small Molecule GLP-1R Agonist, and Begins Phase 2b Study in the US for the Treatment of Obesity [Internet]. Available from: https:\/\/www.prnewswire.com\/news-releases\/regor-releases-phase-2a-topline-results-for-rgt-075-an-oral-once-daily-small-molecule-glp-1r-agonist-and-begins-phase-2b-study-in-the-us-for-the-treatment-of-obesity-302348153.html [cited 2025, Jan 25]."},{"key":"10.23736\/S0031-0808.25.05339-X_ref023","unstructured":"Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290 | Structure Therapeutics [Internet]. Available from: https:\/\/ir.structuretx.com\/news-releases\/news-release-details\/structure-therapeutics-reports-positive-topline-data-its-phase\/ [cited 2025, Feb 25]."},{"key":"10.23736\/S0031-0808.25.05339-X_ref024","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101139"},{"key":"10.23736\/S0031-0808.25.05339-X_ref025","unstructured":"GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals - PubMed [Internet]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32077470\/ [cited 2025, Feb 28]."},{"key":"10.23736\/S0031-0808.25.05339-X_ref026","unstructured":"Lilly E. Lilly Trials. A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities (SURMOUNT-5) [Internet]. Available from: https:\/\/trials.lilly.com\/en-US\/trial\/399775 [cited 2025, Feb 24]."},{"key":"10.23736\/S0031-0808.25.05339-X_ref027","unstructured":"Lilly's Zepbound\u00ae (tirzepatide) superior to Wegovy\u00ae (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7% | Eli Lilly and Company [Internet]. [cited 2025 Feb 24]. Available from: https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-zepboundr-tirzepatide-superior-wegovyr-semaglutide-head [cited 2025, Feb 24]."},{"key":"10.23736\/S0031-0808.25.05339-X_ref028","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401943"},{"key":"10.23736\/S0031-0808.25.05339-X_ref029","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404881"},{"key":"10.23736\/S0031-0808.25.05339-X_ref030","unstructured":"Inc VT. Viking Therapeutics Reports New Data from VK2735 Obesity Program at ObesityWeek\u00ae 2024 [Internet]. Available from: https:\/\/www.prnewswire.com\/news-releases\/viking-therapeutics-reports-new-data-from-vk2735-obesity-program-at-obesityweek-2024-302294915.html [cited 2025, Jan 27]."},{"key":"10.23736\/S0031-0808.25.05339-X_ref031","doi-asserted-by":"publisher","DOI":"10.2337\/db24-1861-LB"},{"key":"10.23736\/S0031-0808.25.05339-X_ref032","unstructured":"Kailera. Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics Report Positive Topline Data from 8 mg Dose of Phase 2 Obesity Trial of GLP-1\/GIP Receptor Dual Agonist HRS9531 [Internet]. Available from: https:\/\/www.kailera.com\/press-release\/jiangsu-hengrui-pharmaceuticals-and-kailera-therapeutics-report-positive-topline-data-from-8-mg-dose-of-phase-2-obesity-trial-of-glp-1-gip-receptor-dual-agonist-hrs9531\/ [cited 2025, Jan 27]."},{"key":"10.23736\/S0031-0808.25.05339-X_ref033","unstructured":"Eschli B. EASD 2024 [Internet]. Investor Relation Presentation presented at; Available from: chrome-extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/assets.roche.com\/f\/176343\/x\/fd3ea522a9\/easd_final_to-share-130924.pdf [cited 2025, Jan 27]."},{"key":"10.23736\/S0031-0808.25.05339-X_ref034","unstructured":"AMGEN. MariTide Update [Internet]. Available from: chrome-extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/investors.amgen.com\/static-files\/0176d78e-920b-45b3-b9cc-a727e58e80da [cited 2025, Jan 21]."},{"key":"10.23736\/S0031-0808.25.05339-X_ref035","doi-asserted-by":"publisher","DOI":"10.2337\/db14-0242"},{"key":"10.23736\/S0031-0808.25.05339-X_ref036","unstructured":"Glucagon increases energy expenditure independently of brown adipose tissue activation in humans - Salem - 2016 - Diabetes, Obesity and Metabolism - Wiley Online Library [Internet]. Available from: https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12585 [cited 2025, Feb 21]."},{"key":"10.23736\/S0031-0808.25.05339-X_ref037","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.07.006"},{"key":"10.23736\/S0031-0808.25.05339-X_ref038","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.141323"},{"key":"10.23736\/S0031-0808.25.05339-X_ref039","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(23)00356-X"},{"key":"10.23736\/S0031-0808.25.05339-X_ref040","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401755"},{"key":"10.23736\/S0031-0808.25.05339-X_ref041","doi-asserted-by":"publisher","DOI":"10.2337\/db24-1856-LB"},{"key":"10.23736\/S0031-0808.25.05339-X_ref042","unstructured":"Biologics I. Innovent Announces Mazdutide Demonstrates 80.2% Reduction in Liver Fat Content in Exploratory Analysis of Phase 3 Weight Management GLORY-1 Study at ADA 2024 [Internet]. Available from: https:\/\/www.prnewswire.com\/news-releases\/innovent-announces-mazdutide-demonstrates-80-2-reduction-in-liver-fat-content-in-exploratory-analysis-of-phase-3-weight-management-glory-1-study-at-ada-2024--302180984.html [cited 2025, Jan 31]."},{"key":"10.23736\/S0031-0808.25.05339-X_ref043","unstructured":"Innovent Biologics Clinical Data Update Mazdutide (IBI362) Higher Dose 9mg Phase 2 Clinical Study in Obesity [Internet]. Available from: chrome-extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/investor.innoventbio.com\/media\/1261\/mazdutide-9mg-higher-dose-phase2-clinical-study-in-obesity.pdf [cited 2025, Jan 26]."},{"key":"10.23736\/S0031-0808.25.05339-X_ref044","doi-asserted-by":"publisher","DOI":"10.2337\/db24-262-OR"},{"key":"10.23736\/S0031-0808.25.05339-X_ref045","doi-asserted-by":"publisher","DOI":"10.1111\/cob.12432"},{"key":"10.23736\/S0031-0808.25.05339-X_ref046","unstructured":"FDA grants fast track designation to Merck's efinopegdutide for treatment of NASH [Internet]. Available from: https:\/\/www.healio.com\/news\/gastroenterology\/20230615\/fda-grants-fast-track-designation-to-mercks-efinopegdutide-for-treatment-of-nash [cited 2025, Feb 21]."},{"key":"10.23736\/S0031-0808.25.05339-X_ref047","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.05.013"},{"key":"10.23736\/S0031-0808.25.05339-X_ref048","unstructured":"A trial to learn how safe AZD9550 is in people with or without type 2 diabetes who are overweight or obese [Internet]. Available from: https:\/\/www.astrazenecaclinicaltrials.com\/study\/D8460C00002\/ [cited 2025, Feb 21]."},{"key":"10.23736\/S0031-0808.25.05339-X_ref049","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2017.11.009"},{"key":"10.23736\/S0031-0808.25.05339-X_ref050","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01751-7"},{"key":"10.23736\/S0031-0808.25.05339-X_ref051","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00275.2010"},{"key":"10.23736\/S0031-0808.25.05339-X_ref052","unstructured":"Taylor NP. Novo Nordisk hails 'remarkable' weight loss result for dual-acting oral drug in early trial | Fierce Biotech [Internet]. Available from: https:\/\/www.fiercebiotech.com\/biotech\/novo-nordisk-hails-remarkable-weight-loss-oral-glp-1-drug [cited 2025 Feb 21]."},{"key":"10.23736\/S0031-0808.25.05339-X_ref053","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2022.07.013"},{"key":"10.23736\/S0031-0808.25.05339-X_ref054","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2301972"},{"key":"10.23736\/S0031-0808.25.05339-X_ref055","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03018-2"},{"key":"10.23736\/S0031-0808.25.05339-X_ref056","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.01307-13"},{"key":"10.23736\/S0031-0808.25.05339-X_ref057","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.33457"},{"key":"10.23736\/S0031-0808.25.05339-X_ref058","first-page":"E990","article-title":"Relationship of resting metabolic rate to body composition and protein turnover","volume":"258","author":"Welle S","year":"1990","journal-title":"Am J Physiol"},{"key":"10.23736\/S0031-0808.25.05339-X_ref059","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-0495(97)90222-5"},{"key":"10.23736\/S0031-0808.25.05339-X_ref060","doi-asserted-by":"publisher","DOI":"10.1002\/oby.23371"},{"key":"10.23736\/S0031-0808.25.05339-X_ref061","doi-asserted-by":"publisher","DOI":"10.1002\/oby.22794"},{"key":"10.23736\/S0031-0808.25.05339-X_ref062","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(23)00191-2"},{"key":"10.23736\/S0031-0808.25.05339-X_ref063","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2023.2930"},{"key":"10.23736\/S0031-0808.25.05339-X_ref064","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30157-3"},{"key":"10.23736\/S0031-0808.25.05339-X_ref065","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309000"},{"key":"10.23736\/S0031-0808.25.05339-X_ref066","unstructured":"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes | New England Journal of Medicine [Internet]. Available from: https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2307563 [cited 2025, Jan 31]."},{"key":"10.23736\/S0031-0808.25.05339-X_ref067","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v2.i2.19"},{"key":"10.23736\/S0031-0808.25.05339-X_ref068","unstructured":"Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 23-26 October 2023 | European Medicines Agency (EMA) [Internet]. Available from: https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-23-26-october-2023 [cited 2025, Feb 11]."},{"key":"10.23736\/S0031-0808.25.05339-X_ref069","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.6586"},{"key":"10.23736\/S0031-0808.25.05339-X_ref070","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-023-06796-9"},{"key":"10.23736\/S0031-0808.25.05339-X_ref071","first-page":"1","article-title":"The effect of obesity pharmacotherapy on body composition, including muscle mass","author":"Argyrakopoulou G","year":"2024","journal-title":"Int J Obes (Lond)"},{"key":"10.23736\/S0031-0808.25.05339-X_ref072","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.24945"},{"key":"10.23736\/S0031-0808.25.05339-X_ref073","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.3224"},{"key":"10.23736\/S0031-0808.25.05339-X_ref074","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2015.59"}],"container-title":["Panminerva Medica"],"original-title":[],"link":[{"URL":"https:\/\/www.minervamedica.it\/pdf.php?cod=R41Y2025N03A0138","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T11:33:20Z","timestamp":1762256000000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.minervamedica.it\/index2.php?show=R41Y2025N03A0138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":74,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.23736\/s0031-0808.25.05339-x","relation":{},"ISSN":["0031-0808","1827-1898"],"issn-type":[{"value":"0031-0808","type":"print"},{"value":"1827-1898","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]}}}